Joan A. Chick

Joan A. Chick

Auto-generated profile, based on publicly available information

Joan A. Chick

Department of Chemical and Biological Engineering, National Higher Polytechnic Institute, The University of Bamenda, Cameroon

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2025 in Heliyon
Verified
Journal Article
Open access
JCJoan A. Chick
Joan A. Chick
NANadege N. Abongdia
Nadege N. Abongdia
RSRobert A. Shey
Robert A. Shey
TATobias O. Apinjoh
Tobias O. Apinjoh
Malaria, a tropical disease, claims the lives of thousands of people annually and the development of resistance to insecticides and antimalarial drugs poses a great challenge to current prevention and control strategies. Current malaria vaccines are limited in efficacy, duration of protection, and safety, due to the high antigenic diversity and complex life cycle of the Plasmodium parasite. This study sought to design and assess a more effective multi-stage, multi-epitope vaccine candidate for the control of malaria. A multi-epitope malaria vaccine candidate was designed in silico using multiple antigens from both the pre-erythrocytic and erythrocytic stages, expressed in bacteria, and its sero-reactivity to antibodies in plasma from malaria-positive (cases) and negative individuals (controls) was assessed using enzyme-linked immunosorbent assay (ELISA). Immunization experiments were equally conducted with BALB/c mice. In-silico analysis revealed that the designed antigen, PfCTMAG (Plasmodium falciparum Circumsporozoite, Thrombospondin-related adhesion protein, Merozoite surface protein 2, Apical asparagine (Asn)-rich protein and Glutamate-Rich Protein), effectively bound to Toll-like receptor 4 (TLR-4) and triggered a strong immune response. In sero-reactivity studies, malaria-positives (cases) had higher anti-PfCTMAG IgG ( p = 0.024) and IgM ( p < 0.001) levels compared to malaria negatives (controls). The mice immunized with PfCTMAG did not show adverse reactions and had higher levels of IgG antibodies (p = 0.002) compared to controls, thereby validating the safety and immunogenicity of PfCTMAG as a promising vaccine candidate.

10 November 2026 in Current Research in Parasitology & Vector-Borne Diseases
Verified
Journal Article
Open access
NYNina Ghislaine Yensii
Nina Ghislaine Yensii
MBMercy Bella-Omunagbe
Mercy Bella-Omunagbe
CFChi Tchampo Fru
Chi Tchampo Fru
FKFabrice Banadzem Kernyuy
Fabrice Banadzem Kernyuy
JCJoan Amban Chick
Joan Amban Chick
Olubanke OgunlanaOlubanke Ogunlana
Olubanke Ogunlana